Harrow Health Inc is trading at $36.89 (+10.25%) after the re-launch of its prescriptive VKC eye treatment, VERKAZIA, sparked renewed investor optimism.
- The stock's performance is particularly notable as it occurs against a risk-off backdrop with major U.S. indexes trending lower.
- Trading volume is currently running above average, indicating strong market interest in the company's latest ophthalmology update.